Xencor logo

Xencor share price today

(XNCR)

Xencor share price is $23.72 & ₹2,035.41 as on 7 Jan 2025, 2.30 'hrs' IST

$23.72

▲

-0.41

(-1.7%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Xencor share price in Dollar and Rupees. Guide to invest in Xencor stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Xencor, along with analyst recommendations, forecasts, and comprehensive financials.

Xencor share price movements

  • Today's Low: $23.72
    Today's High: $24.66

    Day's Volatility :3.81%

  • 52 Weeks Low: $15.31
    52 Weeks High: $27.24

    52 Weeks Volatility :43.8%

Xencor Returns

PeriodXencor IncSector (Health Care)Index (Russel 2000)
3 Months
24.19%
-8.4%
0.0%
6 Months
31.14%
-3.8%
0.0%
1 Year
14.63%
-0.1%
0.0%
3 Years
-36.63%
2.9%
-19.8%

Xencor Key Statistics

in dollars & INR

Previous Close
$24.13
Open
$24.07
Today's High
$24.6599
Today's Low
$23.72
Market Capitalization
$1.7B
Today's Volume
$412.3K
52 Week High
$27.24
52 Week Low
$15.31
Revenue TTM
$85.2M
EBITDA
$-202.5M
Earnings Per Share (EPS)
$-3.18
Profit Margin
-232.77%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-29.02%

How to invest in Xencor from India?

It is very easy for Indian residents to invest directly in Xencor from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Xencor stock in both Indian Rupees (INR) and US Dollars (USD). Search for Xencor or XNCR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Xencor or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Xencor shares which would translate to 0.036 fractional shares of Xencor as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Xencor, in just a few clicks!

Returns in Xencor for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Xencor investment value today

Current value as on today

₹1,15,907

Returns

₹15,907

(+15.91%)

Returns from Xencor Stock

₹12,684 (+12.68%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Xencor

-33%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Xencor on INDmoney from India has reduced in the last 30 days as on Jan 7, 2025. -33% less investors are searching Xencor in the last 30 days versus the previous period.

Global Institutional Holdings in Xencor

  • BlackRock Inc

    15.87%

  • PRIMECAP Management Company

    13.06%

  • Vanguard Group Inc

    10.86%

  • EcoR1 Capital, LLC

    7.62%

  • T. Rowe Price Associates, Inc.

    5.61%

  • Point72 Asset Management, L.P.

    4.46%

Analyst Recommendation on Xencor

Buy

    84%Buy

    10%Hold

    5%Sell

Based on 19 Wall street analysts offering stock ratings for Xencor(by analysts ranked 0 to 5 stars)

Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
17
Hold
2
2
1
Sell
1
1
1

Analyst Forecast on Xencor

What analysts predicted

Upside of 38.74%

Current:

$23.72

Target:

$32.91

Insights on Xencor

  • Price Movement

    In the last 3 months, XNCR stock has moved up by 21.6%

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 16.96M → 10.71M (in $), with an average decrease of 36.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -68.03M → -45.14M (in $), with an average increase of 24.6% per quarter

  • XNCR vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 6.5%

  • XNCR vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 94.1%

  • Price to Sales

    ForXNCR every $1 of sales, investors are willing to pay $17.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Xencor Financials in INR & Dollars

FY18Y/Y Change
Revenue
$40.6M
↑ 13.7%
Net Income
$-70.4M
↑ 43.91%
Net Profit Margin
-173.41%
↓ 36.41%
FY19Y/Y Change
Revenue
$156.7M
↑ 285.93%
Net Income
$26.9M
↓ 138.17%
Net Profit Margin
17.15%
↑ 190.56%
FY20Y/Y Change
Revenue
$122.7M
↓ 21.7%
Net Income
$-63.5M
↓ 336.42%
Net Profit Margin
-51.79%
↓ 68.94%
FY21Y/Y Change
Revenue
$275.1M
↑ 124.23%
Net Income
$82.6M
↓ 230.05%
Net Profit Margin
30.04%
↑ 81.83%
FY22Y/Y Change
Revenue
$164.6M
↓ 40.18%
Net Income
$-55.2M
↓ 166.78%
Net Profit Margin
-33.53%
↓ 63.57%
FY23Y/Y Change
Revenue
$168.3M
↑ 2.28%
Net Income
$-126.1M
↑ 128.5%
Net Profit Margin
-74.9%
↓ 41.37%
Q2 FY23Q/Q Change
Revenue
$45.5M
↑ 140.07%
Net Income
$-22.0M
↓ 63.36%
Net Profit Margin
-48.23%
↑ 267.75%
Q3 FY23Q/Q Change
Revenue
$59.2M
↑ 29.97%
Net Income
$-24.3M
↑ 10.54%
Net Profit Margin
-41.02%
↑ 7.21%
Q4 FY23Q/Q Change
Revenue
$44.7M
↓ 24.47%
Net Income
$-19.1M
↓ 21.3%
Net Profit Margin
-42.74%
↓ 1.72%
Q1 FY24Q/Q Change
Revenue
$12.8M
↓ 71.35%
Net Income
$-68.0M
↑ 256.19%
Net Profit Margin
-531.3%
↓ 488.56%
Q2 FY24Q/Q Change
Revenue
$17.0M
↑ 32.45%
Net Income
$-66.0M
↓ 3.04%
Net Profit Margin
-388.93%
↑ 142.37%
Q3 FY24Q/Q Change
Revenue
$10.7M
↓ 36.85%
Net Income
$-45.1M
↓ 31.56%
Net Profit Margin
-421.5%
↓ 32.57%
FY18Y/Y Change
Profit
$40.6M
↑ 13.7%
FY19Y/Y Change
Profit
$38.1M
↓ 6.14%
FY20Y/Y Change
Profit
$122.7M
↑ 221.95%
FY21Y/Y Change
Profit
$275.1M
↑ 124.23%
FY22Y/Y Change
Profit
$164.6M
↓ 40.18%
FY23Y/Y Change
Profit
$-85.3M
↓ 151.8%
Q2 FY23Q/Q Change
Profit
$42.6M
↑ 155.06%
Q3 FY23Q/Q Change
Profit
$56.0M
↑ 31.39%
Q4 FY23Q/Q Change
Profit
$41.5M
↓ 25.99%
Q1 FY24Q/Q Change
Profit
$9.8M
↓ 76.44%
Q2 FY24Q/Q Change
Profit
$13.9M
↑ 42.64%
Q3 FY24Q/Q Change
Profit
$10.7M
↓ 23.15%
FY18Y/Y Change
Operating Cash Flow
$-79.8M
↑ 136.78%
Investing Cash Flow
$-164.8M
↓ 615.7%
Financing Cash Flow
$254.2M
↑ 6710.63%
FY19Y/Y Change
Operating Cash Flow
$64.4M
↓ 180.71%
Investing Cash Flow
$-51.0M
↓ 69.07%
Financing Cash Flow
$10.7M
↓ 95.81%
FY20Y/Y Change
Operating Cash Flow
$-5.0M
↓ 107.77%
Investing Cash Flow
$100.2M
↓ 296.57%
Financing Cash Flow
$18.0M
↑ 69.24%
FY21Y/Y Change
Operating Cash Flow
$-16.9M
↑ 236.79%
Investing Cash Flow
$-46.2M
↓ 146.16%
Financing Cash Flow
$43.0M
↑ 138.52%
FY22Y/Y Change
Operating Cash Flow
$24.5M
↓ 245.29%
Investing Cash Flow
$-119.7M
↑ 158.87%
Financing Cash Flow
$5.7M
↓ 86.75%
Q2 FY23Q/Q Change
Operating Cash Flow
$-38.2M
↑ 24.78%
Investing Cash Flow
$-1.4M
↓ 102.92%
Financing Cash Flow
$1.9M
↑ 108.35%

Xencor Technicals Summary

Sell

Neutral

Buy

Xencor is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Xencor Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Xencor Inc
Xencor Inc
-4.25%
31.14%
14.63%
-36.63%
-30.38%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Xencor Inc
Xencor Inc
70.49
NA
0.0
-3.68
-0.29
-0.15
NA
10.35
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Xencor Inc
Xencor Inc
Buy
$1.7B
-30.38%
70.49
-232.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Xencor

antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product
Organization
Xencor
Employees
280
CEO
Dr. Bassil I. Dahiyat Ph.D.
Industry
Health Technology

Management People of Xencor

NameTitle
Dr. Bassil I. Dahiyat Ph.D.
Co-Founder, CEO, President & Director
Dr. John R. Desjarlais Ph.D.
Executive VP of Research & Chief Scientific Officer
Ms. Celia E. Eckert J.D.
Senior VP, General Counsel & Corporate Secretary
Dr. Nancy Valente M.D.
Executive VP & Chief Development Officer
Mr. Bart Jan Cornelissen
Senior VP & CFO
Mr. Charles Liles
Associate Director and Head of Corporate Communications & Investor Relations
Ms. Jennifer Sandoz
Senior VIce President of Human Resources
Dr. Jeremy Grunstein Ph.D.
Senior Vice President of Business Development
Mr. Kirk Rosemark RAC
Senior Vice President of Regulatory Affairs & Quality Assurance
Mr. Eric P. Kowack
Senior Vice President of Program Leadership & Alliance Management

Important FAQs about investing in Xencor from India :

What is Xencor share price today?

Xencor share price today stands at $23.72, Open: $24.07 ; Previous Close: $24.13 ; High: $24.66 ; Low: $23.72 ; 52 Week High: $27.24 ; 52 Week Low: $15.31. The stock opens at $24.07, after a previous close of $24.13. The stock reached a daily high of $24.66 and a low of $23.72, with a 52-week high of $27.24 and a 52-week low of $15.31.

Can Indians buy Xencor shares?

Yes, Indians can invest in the Xencor (XNCR) from India.

With INDmoney, you can buy Xencor at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Xencor at zero transaction cost.

How can I buy Xencor shares from India?

It is very easy to buy Xencor from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Xencor be purchased?

Yes, you can buy fractional shares of Xencor with INDmoney app.

What are the documents required to start investing in Xencor stocks?

To start investing in Xencor, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Xencor

Today’s highest price of Xencor (XNCR) is $24.66.

Today’s lowest price of Xencor (XNCR) is $23.72.

What is today's market capitalisation of Xencor

Today's market capitalisation of Xencor XNCR is 1.7B

What is the 52 Week High and Low Range of Xencor

  • 52 Week High

    $27.24

  • 52 Week Low

    $15.31

What are the historical returns of Xencor?

  • 1 Month Returns

    -4.25%

  • 3 Months Returns

    31.14%

  • 1 Year Returns

    14.63%

  • 5 Years Returns

    -30.38%

Who is the Chief Executive Officer (CEO) of Xencor

Dr. Bassil I. Dahiyat Ph.D. is the current Chief Executive Officer (CEO) of Xencor.